Physician profile
Michael Valerio
NPI 1487372512
$2,265.27
in general payments reported to CMS, 2019-2025
24 companies · $1,455 in 2025
The $1,455 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $80.63 · 2023: $392 · 2024: $338 · 2025: $1,455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,184.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $297.69 | 2025 | Lifevest |
| Novo Nordisk INC | $251.06 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $222.80 | 2022-2025 | Delstrigo, Pifeltro, Verquvo |
| Novartis Pharmaceuticals Corporation | $210.43 | 2023-2025 | |
| Amgen INC. | $151.06 | 2025 | Repatha |
| Astrazeneca Pharmaceuticals LP | $134.59 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Exact Sciences Corporation | $120.81 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $91.22 | 2022-2025 | |
| Lilly USA, LLC | $88.65 | 2023-2024 | Mounjaro |
| Abbvie INC. | $88.33 | 2023-2025 | |
| Viiv Healthcare Company | $83.82 | 2023-2025 | Dovato, Cabenuva |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.42 | 2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $70.70 | 2025 | Camzyos, Eliquis |
| Alnylam Pharmaceuticals INC. | $66.78 | 2025 | Onpattro |
| Philips North America LLC | $62.13 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.01 | 2024-2025 | Xifaxan, Trulance |
| Abiomed | $45.78 | 2023 | Impella |
| Theratechnologies INC. | $35.30 | 2023 | Egrifta, Trogarzo |
| Boston Scientific Corporation | $24.33 | 2025 | Cds - Mct/Cem Monitoring |
| Zoll Medical Corporation | $24.10 | 2025 | Defibrillator |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.86 | 2024 | Caplyta |
| Impulse Dynamics (USA) INC. | $17.83 | 2025 | Optimizer |
| Janssen Biotech, INC. | $13.83 | 2022 | |
| Glaxosmithkline, LLC. | $13.74 | 2025 | Arexvy, Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Valerio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.